CD19 and acute lymphoblastic leukemia: CARTs targeting CD19, a ubiquitously expressed B-cell surface antigen, have induced durable, sustained antitumor immune responses in patients with acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia, multiple myeloma, and treatment-refractory diffuse large B-cell lymphoma (DLBCL) (7–13).